Eli Lilly (LLY) to Discontinue One Tabalumab Phase 3 Study; Sees Q4 Charge

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. SPY
4. WMT
5. ADI
6. ROST
7. BILL
8. MRK
9. MRNA
10. COTY

Go back to Eli Lilly (LLY) to Discontinue One Tabalumab Phase 3 Study; Sees Q4 Charge
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1244.40 -35.94 (2.81%)
Previous Close $1280.34    52 Week High $88.16 
Open $1274.13    52 Week Low $67.88 
Day High $1280.28    P/E 288.06 
Day Low $1243.23    EPS $4.32 
Volume 2,617,373